Evidence map›Paper›PMID 38435522›Full record

ReviewACS central science2024

Opportunities and Challenges for Machine Learning-Assisted Enzyme Engineering.

Jason Yang, Francesca-Zhoufan Li, Frances H Arnold

Abstract readReview
In one paragraph

Review in ACS central science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Next-Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca.Chembiochem : a European journal of chemical biology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Applications and limitations of AI tools in enzyme design.Protein science : a publication of the Protein Society · 2026
    Review
  12. Semiartificial COChemical reviews · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason YangDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.ORCID https://orcid.org/0000-0003-3184-1550
Francesca-Zhoufan LiDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, California 91125, United States.ORCID https://orcid.org/0000-0002-5710-9512
Frances H ArnoldDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.ORCID https://orcid.org/0000-0002-4027-364X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzymes can be engineered at the level of their amino acid sequences to optimize key properties such as expression, stability, substrate range, and catalytic efficiency-or even to unlock new catalytic activities not found in nature. Because the search space of possible proteins is vast, enzyme engineering usually involves discovering an enzyme starting point that has some level of the desired activity followed by directed evolution to improve its "fitness" for a desired application. Recently, machine learning (ML) has emerged as a powerful tool to complement this empirical process. ML models can contribute to (1) starting point discovery by functional annotation of known protein sequences or generating novel protein sequences with desired functions and (2) navigating protein fitness landscapes for fitness optimization by learning mappings between protein sequences and their associated fitness values. In this Outlook, we explain how ML complements enzyme engineering and discuss its future potential to unlock improved engineering outcomes.

Identifiers

PMID38435522
PMCPMC10906252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.